{"id":390739,"date":"2018-02-21T00:00:00","date_gmt":"2018-02-21T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algomd0025-2018-biopharma-gout-treatment-algorithms-claims-data-analysis-us-2018\/"},"modified":"2026-05-15T23:20:11","modified_gmt":"2026-05-15T23:20:11","slug":"algomd0025-2018-biopharma-gout-treatment-algorithms-claims-data-analysis-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algomd0025-2018-biopharma-gout-treatment-algorithms-claims-data-analysis-us-2018\/","title":{"rendered":"Gout | Treatment Algorithms | Claims Data Analysis | US | 2018"},"content":{"rendered":"<p>Gout is a chronic condition characterized by intermittent acute flares caused by elevated serum uric acid (<abbr data-original-title=\"serum uric acid\" title=\"\">sUA<\/abbr>). Treatment of the painful acute flares is distinct from the chronic management of hyperuricemia with urate-lowering therapies and is not considered in this study. Xanthine oxidase inhibitors (<abbr data-original-title=\"xanthine oxidase inhibitor\" title=\"\">XOI<\/abbr>s) are the mainstay of chronic gout treatment, with generic allopurinol prescribed much more extensively than the brands Uloric and Zurampic. Gout Treatment Algorithms presents urate-lowering therapy prescribing patterns and provides insights into the uptake of novel branded agents against the background of generic allopurinol dominance.<\/p>\n<p>QUESTIONS ANSWERED:<\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed gout patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed gout patients?<\/li>\n<li>How has Zurampic and Krystexxa been integrated into the treatment algorithm?<\/li>\n<li>What proportion of gout patients receive drug therapy within one year of diagnosis, and how quickly?<\/li>\n<li>What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of gout patients are treated with monotherapy versus combination therapy?<\/li>\n<li>What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with gout?<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390739","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-gout","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390739\/revisions"}],"predecessor-version":[{"id":393863,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390739\/revisions\/393863"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}